Payers Waive Cost Sharing and Prior Authorization for COVID-19 Treatment

In an effort to help ease cost concerns for those infected with COVID-19, the disease caused by the novel coronavirus, several health insurance companies have waived cost sharing requirements related to COVID-19 treatment. They include:

Aetna (owned by CVS Health Corp.), in network

Anthem, Inc., through May 31

Always Health Partners Inc., in network

Blue Cross Blue Shield of Massachusetts

Blue Cross Blue Shield of North Carolina

Centene Corp.

Cigna Corp., through May 31

Dean Health Plan Inc., in network

Florida Blue

Harvard Pilgrim Health Care

Health Care Service Corp.

Horizon Blue Cross Blue Shield of New Jersey, through “at least June 30” and retroactive to March 1

Humana Inc.

L.A. Care Health Plan

UnitedHealth Group, through May 31.

0 Comments
© 2024 MMIT
Peter Johnson

Peter Johnson

Peter has worked as a journalist since 2011 and has covered health care since 2020. At AIS Health, Peter covers trends in finance, business and policy that affect the health insurance and pharma sectors. For Health Plan Weekly, he covers all aspects of the U.S. health insurance sector, including employer-sponsored insurance, Medicaid managed care, Medicare Advantage and the Affordable Care Act individual marketplaces. In Radar on Drug Benefits, Peter covers the operations of (and conflicts between) pharmacy benefit managers and pharmaceutical manufacturers, with a particular focus on pricing dynamics and market access. Before joining AIS Health, Peter covered transportation, public safety and local government for various outlets in Seattle, his hometown and current place of residence. He graduated with a B.A. from Colby College.

Related Posts

medicare-part-c
May 17

Medicare, Medicaid Segments May Be a ‘Mess,’ but Bounce-Back Expected

READ MORE
hospital-hallway
May 17

As Hospitals’ Commercial Prices Keep Rising, Experts Float Solutions

READ MORE
businessman-viewing-news-update-journalism-headline-on-a-laptop
May 17

News Briefs: CMS Extends Medicaid Redetermination Deadline

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today